Novai is developing DARC technology
To preserve sight through early detection and treatment of ophthalmic disease using a novel real-time cellular platform technology combining a biologic (Annexin-776) with AI, thereby bringing value to patients, providers and our pharmaceutical clients.
how we improve patient outcomes
DARC
Biomarker
Supporting pharma and biotech drug development in ophthalmic indications, by de-risking and accelerating clinical trials
DARC Diagnostic
Develop early glaucoma detection as a first indication & enable active disease management, greatly improving patient outcomes
DARC Drug Delivery
Expand scope of DARC biologic molecule as a targeted drug delivery vehicle which can overcome biological barriers known to impede drug delivery to eye and brain
why novai?
Our biomarker rapidly measures the impact of current and future therapeutics and interventions by assessment of disease activity in vivo, using DARC metrics
DARC helps stratify patients in clinical trials, resulting in the creation of enriched patient cohorts and identifies non-responders to existing and new interventions
By easily implementing DARC into your pre-clinical or clinical trials, you could avoid ineffective medical management and de-risk your ophthalmic trials
HOW DARC BENEFITS PHARMACEUTICAL CLIENTS
Our robust technology can be tailored to your unique design, maximising the success of your glaucoma or AMD trial. By delivering DARC in a clearly outlined full-service model, we can boost efficiency, quickly determine efficacy and save you time and money.
Click below to learn more
our publications
See below a sample of our research publications, click to read
novai awards
Novai is a finalist for the BIO Start-up Stadium Competition, 2021.
Novai wins best Newcomer in the Clinical Trial Excellence Award 2020.
Novai comes second in the finals for the Shenzhen Innovation & Entrepreneurship International Competition 2020.